Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rodeberg DA et al. – CR status at the end of protocol therapy in clinical group III participants was not associated with a reduction of disease recurrence and death. Aggressive alternative therapy may not be warranted for RMS patients with a residual mass at the end of planned therapy.

Related Articles

Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells
British Journal of Cancer, 11/06/09    Relevance Score: 87%

Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma
European Journal of Cancer, 10/01/09    Relevance Score: 87%

A rare case of paratesticular pleomorphic rhabdomyosarcoma diagnosed by fine needle aspiration: A case report
Diagnostic Cytopathology, 10/02/09    Relevance Score: 85%

Laparoscopic Retroperitoneal Lymph Node Dissection for High-Risk Pediatric Patients with Paratesticular Rhabdomyosarcoma
Journal of Endourology, 10/27/09    Relevance Score: 83%

First Case Report of Bilateral Metastatic Intratesticular Rhabdomyosarcoma
Urology, 10/26/09    Relevance Score: 83%

Today in Pharmacology/Therapy...keeping you current

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy
Journal of Clinical Oncology, 12/17/09

Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells
Cancer Chemotherapy and Pharmacology, 12/17/09

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma
Journal of Clinical Oncology, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address